Koh J, Shiina E, Hosoda Y, Hashimoto M, Yamamoto O, Sakai S, Kubota T, Enomoto K, Abe O
Department of Surgery, Social Insurance Saitama Chuo Hospital, Japan.
Jpn J Surg. 1990 Jan;20(1):89-96. doi: 10.1007/BF02470719.
We examined the effect of chemotherapeutic agents on the estrogen receptors (ER) of breast carcinomas in vivo using human breast carcinoma strains (Br-10, T-61) serially transplanted into nude mice. When the tumor size reached approximately 1 X 1 X 1 cm, mitomycin C (MMC) at doses of 1, 2 and 4.5 mg/kg and cyclophosphamide (CPA) at a dose of 120 mg/kg, were administered once intraperitoneally, and the ERs of the tumors were measured sequentially by the dextran-coated charcoal method. Four days after the MMC administration at above doses, the binding sites of ER in Br-10 were not reduced and binding affinity was not affected. When the changes in ER content with time after the treatment with 4.5 mg/kg MMC and 120 mg/kg CPA were investigated, the ER content was found to be stable until 4 days after the treatment with both drugs, although the growth of T-61 had been significantly inhibited by the drugs. From these findings, it seems reasonable to initiate chemotherapy before endocrine therapy, since the chemotherapeutic agents did not reduce the ER content of the breast cancer strains.
我们使用连续移植到裸鼠体内的人乳腺癌细胞系（Br-10、T-61），在体内研究了化疗药物对乳腺癌雌激素受体（ER）的影响。当肿瘤大小达到约1×1×1厘米时，腹腔注射一次剂量为1、2和4.5毫克/千克的丝裂霉素C（MMC）以及剂量为120毫克/千克的环磷酰胺（CPA），并通过葡聚糖包被活性炭法依次测量肿瘤的ER。在上述剂量的MMC给药后4天，Br-10中ER的结合位点未减少，结合亲和力也未受影响。当研究用4.5毫克/千克MMC和120毫克/千克CPA治疗后ER含量随时间的变化时，发现两种药物治疗后4天内ER含量保持稳定，尽管T-61的生长已被药物显著抑制。从这些发现来看，在内分泌治疗之前启动化疗似乎是合理的，因为化疗药物并未降低乳腺癌细胞系的ER含量。
